Class Action Lawsuit Against Actinium Pharmaceuticals
Attention, investors! A significant class action lawsuit has been initiated against Actinium Pharmaceuticals, Inc. This lawsuit is aimed at individuals who have suffered financial losses related to their investments in Actinium Pharmaceuticals (NYSE: ATNM). The lawsuit is being spearheaded by the experienced legal team from Levi & Korsinsky, LLP, known for their dedication to securing justice for investors.
Understanding The Class Definition
The primary focus of this lawsuit is to recover losses for investors who were negatively impacted by alleged fraudulent activities over a specific period. This encompasses claims of securities fraud that took place from October 31, 2022, to August 2, 2024. The team is encouraging all affected investors to seek more information about their legal rights and options.
Details of The Case
The allegations within the court filings indicate that the defendants might have misled investors by making untrue statements. The lawsuit contends that the company’s data gathered from the Phase 3 Sierra trial may not have met the FDA's required standards for approval of its targeted radiotherapy treatment, known as Iomab-B BLA. Additional analyses provided to the FDA, which were claimed to showcase improvements in overall survival rates, are purportedly also at risk of not satisfying FDA guidelines. Consequently, there is concern that the FDA may refuse to review the BLA application or in its current form, it may not receive approval.
Next Steps for Affected Investors
Investors who incurred losses during the designated time frame are urged to act quickly. They have a deadline approaching for May 27, 2025, to file a request to be appointed as lead plaintiff. It is important to note, however, that participation in any recovery does not necessitate serving as a lead plaintiff.
No Financial Obligation to Participate
Acting as a class member presents an opportunity for compensation without the burden of out-of-pocket costs or fees. This means that you can participate without financial risks or obligations.
Why Choose Levi & Korsinsky
Levi & Korsinsky brings over two decades of experience and has successfully garnered hundreds of millions of dollars for shareholders. Their skilled team in complex securities litigation is well-equipped to handle such high-stakes cases. Additionally, they boast of a strong ranking in the ISS Securities Class Action Services' Top 50 Report, highlighting their position as one of the leading firms in the field of securities litigation across the nation.
Contact Information
If you are interested in pursuing this case or learning more about your rights as an investor, you may contact Levi & Korsinsky, LLP. Reach out to Joseph E. Levi, Esq. or Ed Korsinsky, Esq. at their office located at 33 Whitehall Street, 17th Floor, New York, NY 10004. You can call them at (212) 363-7500 for any inquiries you might have, or visit their website for additional details.
Frequently Asked Questions
What is the purpose of the class action lawsuit?
The class action lawsuit aims to recover financial losses for investors of Actinium Pharmaceuticals who were affected by alleged securities fraud.
What time frame does the lawsuit cover?
The lawsuit pertains to events that occurred between October 31, 2022, and August 2, 2024.
What should I do if I lost money investing in Actinium?
If you suffered a loss, consider reaching out to Levi & Korsinsky to explore your legal options.
Are there costs associated with participating in the lawsuit?
No, there are no out-of-pocket costs or fees for class members who wish to participate.
How can I contact the legal team?
You can call Levi & Korsinsky at (212) 363-7500 or visit their office for more information on the class action lawsuit.
